Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to Buy from Neutral, raising its price target to $65 from $46. Analyst Michael Yee noted a severely skewed risk/reward ratio to the potential in the latter half of 2026, with three to four key triggers that may propel the stock up as much as 25%.

The firm highlighted that Bristol-Myers Squibb Company (NYSE:BMY) will face loss of exclusivity challenges up to 2028, resulting in consensus reservations and a fairly low price-to-earnings ratio of 9x. Despite these obstacles, UBS estimates that the current stock price reflects the majority of the $20-30 billion LOE damage projected through 2028, albeit failing to account for future positive developments.

Bristol-Myers Squibb Company (NYSE:BMY) also showed recent findings at the American Society of Hematology Annual Meeting, highlighting updates on its lymphoma treatments, including the experimental drug golcadomide and the CAR T cell therapy Breyanz.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharma‌ceutical company that⁠ discovers, dev⁠e​lo‌p‌s, a⁠nd manufactures innovative medicines to treat ser⁠ious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.